Valeant Pharmaceuticals International, Inc.
GPTKB entity
Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Bausch_&_Lomb
|
| gptkbp:acquisitionYear |
2013
|
| gptkbp:countryOfOrigin |
gptkb:Canada
|
| gptkbp:founded |
1960
|
| gptkbp:founder |
gptkb:Milan_Panić
|
| gptkbp:headquartersLocation |
gptkb:Laval,_Quebec,_Canada
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:keyPerson |
gptkb:Joseph_C._Papa
gptkb:J._Michael_Pearson |
| gptkbp:notableEvent |
subject of U.S. Senate investigations
involved in major accounting and pricing controversies |
| gptkbp:numberOfEmployees |
~22,000 (2016)
|
| gptkbp:products |
medical devices
over-the-counter drugs prescription drugs |
| gptkbp:renamed |
gptkb:Bausch_Health_Companies_Inc.
2018 |
| gptkbp:successor |
gptkb:Bausch_Health_Companies_Inc.
|
| gptkbp:tradedOn |
gptkb:NYSE:_VRX
gptkb:TSX:_VRX |
| gptkbp:website |
www.valeant.com
|
| gptkbp:bfsParent |
gptkb:Bausch_Health_Companies_Inc.
gptkb:Biovail gptkb:VRX gptkb:NYSE:BHC gptkb:TSX:BHC |
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
Valeant Pharmaceuticals International, Inc.
|